De-risking Drug Development with Mechanistic Insights

Custom QSP Models for Clearer Decisions, Built with Collaboration and Transparency, Without Licensing Fees

PhysioPD Research

PhysioPD Research is a proprietary approach that translates the physiology, disease pathophysiology, and drug pharmacology of interest into a customized and interactive mathematical Research Platform. PhysioPD delivers credible insights that would be impossible to obtain in any other way. It is used by scientists and clinicians to clarify the connection between disease mechanisms, therapeutic interventions, and clinical outcomes. The result is that decision-makers have a dramatic increase in confidence to develop successful clinical trials and product submissions.

Learn more about PhysioPD Research
PhysioPD Research

Trusted Partners in Pharmaceutical Innovation

For over two decades, Rosa & Co. has partnered with top pharmaceutical and biotechnology companies to unlock the potential of their therapies. These are just a selection of companies that have published with us. Our work helps understand mechanisms of action, optimize dosing strategies, identify key biomarkers, and predict clinical outcomes. Discover the transformative insights our collaborations have generated. Read our case studies or contact us to learn more.

Go to Disease Area

Explore our Worldwide Webinar Series

Rosa’s "Impact" webinar series is renowned for its informative discussions on the use of computer modeling and simulation within the global research and development community. Register for an upcoming webinar or download a webinar from the archives.

Explore Webinars
Explore our Worldwide Webinar Series

Recent Highlights

Rosa & Co Presentations at ACoP 2025

Rosa & Co will present three posters at the 2025 American Conference on Pharmacometrics (ACoP2025) at the Gaylord Rockies in Aurora, Colorado from Oct 18 to 21. Poster Session: Tuesday, October 21 "Accurate modeling of ACTH and cortisol dynamics for Cu... Read More

Rosa & Co. announces the publication of an article using virtual patients and multiomics to predict efficacy of a cutaneous lupus therapy.

Rosa & Co. announced today the publication of an article titled, "Virtual patients inspired by multiomics predict the efficacy of an anti-IFNα mAb in cutaneous lupus." Rosa & Co. co-published the article with Servier, Research and Development and GENY... Read More